The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing (BIOPRES)
Primary Purpose
Prostate Cancer
Status
Unknown status
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
TRUS probe
Sponsored by
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring prostate cancer, biopsy, TRUS, diagnosis
Eligibility Criteria
Inclusion Criteria:
- PSA and DRE performed in advance of the biopsy
- Informed consent
- Number of biopsy cores according to the volume dependent biopsy protocol (8 cores in prostates with a volume less than 40 mL., 10 in 40-60 mL. and 12 in >60 mL.)
Exclusion Criteria:
- None
Sites / Locations
- Amphia hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Side-firing
End-firing
Arm Description
prostate biopsies obtained with side-firing probe
Outcomes
Primary Outcome Measures
The presence of prostate cancer in the tissue obtained by prostate needle biopsy
Secondary Outcome Measures
Number of cores invaded with prostate cancer
Gleason score
Complications
Biopsy length
Nomogram score for indolent prostate cancer
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00851292
Brief Title
The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing
Acronym
BIOPRES
Official Title
The BIOPRES Trial; Transrectal BIOpsies of the PRostate: End Versus Side-firing
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Unknown status
Study Start Date
October 2009 (undefined)
Primary Completion Date
September 2012 (Anticipated)
Study Completion Date
September 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Amphia Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to study the difference in prostate cancer between two prostate biopsy techniques, namely end-firing and side-firing. These differ in the angle at which the prostate is biopsied.
Detailed Description
Rationale: Research towards the efficacy of transrectal prostate biopsies has predominantly focused on the amount of biopsy cores. However, variation in the angle of entrance of the biopsy gun has been less studied. It is believed that obtaining biopsy cores by end firing will improve the efficacy, because of an improved sampling of the apical region.
Objectives: To investigate the difference between side and end-firing in transrectal prostate needle biopsies in terms of qualitative and quantitative prostate cancer detection.
Methods: From September 1st 2009 - September 1st 2012, all men with an initial prostate biopsy in a representative, Dutch, general hospital with six participating urologists and two residents will be subjected to a randomized controlled, single blind, single center, diagnostics trial. Men will be randomized for a biopsy using an end-firing or a side-firing probe. The primary endpoint is the prostate cancer detection rate; secondary endpoints are the number of cores invaded with prostate cancer, nomogram for indolent cancer-score, Gleason score, complications and biopsy length.
Expected outcomes: We hypothesize that no differences between the biopsy techniques exist.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
prostate cancer, biopsy, TRUS, diagnosis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
800 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Side-firing
Arm Type
Active Comparator
Arm Description
prostate biopsies obtained with side-firing probe
Arm Title
End-firing
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
TRUS probe
Intervention Description
end-firing and side-firing vary in the angle in which they sample the prostate
Primary Outcome Measure Information:
Title
The presence of prostate cancer in the tissue obtained by prostate needle biopsy
Time Frame
This outcome parameter will be available 5 days after the biopsy has been done. E.g. there will be virtually no 'follow-up' period.
Secondary Outcome Measure Information:
Title
Number of cores invaded with prostate cancer
Time Frame
All secondary outcome measures, except for the complications will be available when the pathology report emerges. Initial complications will be registered after 2 weeks.
Title
Gleason score
Time Frame
All secondary outcome measures, except for the complications will be available when the pathology report emerges. Initial complications will be registered after 2 weeks.
Title
Complications
Time Frame
All secondary outcome measures, except for the complications will be available when the pathology report emerges. Initial complications will be registered after 2 weeks.
Title
Biopsy length
Time Frame
All secondary outcome measures, except for the complications will be available when the pathology report emerges. Initial complications will be registered after 2 weeks.
Title
Nomogram score for indolent prostate cancer
Time Frame
All secondary outcome measures, except for the complications will be available when the pathology report emerges. Initial complications will be registered after 2 weeks.
10. Eligibility
Sex
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
PSA and DRE performed in advance of the biopsy
Informed consent
Number of biopsy cores according to the volume dependent biopsy protocol (8 cores in prostates with a volume less than 40 mL., 10 in 40-60 mL. and 12 in >60 mL.)
Exclusion Criteria:
None
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stijn Roemeling, MD, PhD
Email
sroemeling@amphia.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stijn Roemeling, MD, PhD
Organizational Affiliation
Amphia Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amphia hospital
City
Breda
State/Province
Noord-Brabant
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stijn Roemeling, MD, PhD
12. IPD Sharing Statement
Learn more about this trial
The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing
We'll reach out to this number within 24 hrs